But while the company labels itself a drug company, and pledges to get into generic drug manufacturing of its own in a Dallas-based cGMP facility, the company is really planning to operate as a compounding pharmacy.
Alex Oshmyansky
“At launch, we are planning as functioning primarily as a 503(b) compounding pharmacy specifically targeting drugs on the FDA shortage list,” CEO Alex Oshmyansky told Endpoints News via email. “That will allow us to be more agile and address drug shortages as they arise.
